Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double- Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study.,Gut and Liver

当前位置： X-MOL 学术 › Gut Liver › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double- Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study.
Gut and Liver ( IF 3.4 ) Pub Date : 2021-04-07 , DOI: 10.5009/gnl20338
Gwang Ha Kim ₁ , Hang Lak Lee ₂ , Moon Kyung Joo ₃ , Hong Jun Park ₄ , Sung Woo Jung ₅ , Ok-Jae Lee ₆ , Hyungkil Kim ₇ , Hoon Jai Chun ₈ , Soo Teik Lee ₉ , Ji Won Kim ₁₀ , Han Ho Jeon ₁₁ , Il-Kwun Chung ₁₂ , Hyun-Soo Kim ₁₃ , Dong Ho Lee ₁₄ , Kyoung-Oh Kim ₁₅ , Yun Jeong Lim ₁₆ , Seun-Ja Park ₁₇ , Soo-Jeong Cho ₁₈ , Byung-Wook Kim ₁₉ , Kwang Hyun Ko ₂₀ , Seong Woo Jeon ₂₁ , Jae Gyu Kim ₂₂ , In-Kyung Sung ₂₃ , Tae Nyeun Kim ₂₄ , Jae Kyu Sung ₂₅ , Jong-Jae Park ₃

Affiliation

Department of Internal Medicine, Pusan National University College of Medicine, and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Department of Internal Medicine, Hanyang University Hospital, Seoul, Korea.
Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Division of Gastroenterology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea.
Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Jeonbuk National University Hospital, Jeonju, Korea.
Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University of College of Medicine, Seoul, Korea.
Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Department of Internal Medicine, Dongguk University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.

: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta^Ⓡ (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis.

中文翻译：

瑞巴派特与其新制剂 AD-203 在糜烂性胃炎患者中的疗效和安全性：一项随机、双盲、主动对照、非劣效性、多中心、3 期研究。

：粘膜保护药物瑞巴派特用于治疗胃炎和消化性溃疡。我们比较了 Mucosta ^Ⓡ（瑞巴派特 100 毫克）及其新制剂 AD-203（瑞巴派特 150 毫克）在治疗糜烂性胃炎方面的功效。

更新日期：2021-04-11

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>